Filtered Listing Testing
A new BrightFocus-funded study suggests that an FDA-approved sleeping pill may slow or stop the progression of Alzheimer’s disease, promising findings that are sparking further investigation.
The 2023 Helen Keller Laureates Gustavo D. Aguirre, VMD, PhD, Jean Bennett, MD, PhD, Samuel G. Jacobson, MD, PhD (posthumously), Albert M. Maguire, MD, and T. Michael Redmond, PhD, were awarded the 2023 Helen Keller Prize for Vision Research on April 25 by BrightFocus Foundation and the Helen Keller Foundation for Research and Education.
BrightFocus Foundation was honored on April 22 by the Association for Research in Vision and Ophthalmology (ARVO) in New Orleans.
BrightFocus Foundation, an international nonprofit funder of brain and vision research, recognized five leading vision scientists for their ideas to prevent, treat, and cure macular degeneration and glaucoma during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
A BrightFocus-funded research team has some eye-opening news: They’ve used artificial intelligence to develop a model that could one day detect Alzheimer’s disease through photographs of the eye, which could lead to earlier diagnosis and treatment.
BrightFocus Foundation will support a new five-year research initiative in Canada that will study the aging brain and identify how to reduce the risks of dementia and other forms of cognitive impairment.
Register for our new Zoom in on Dementia & Alzheimer’s program, a free, monthly, virtual discussion series featuring medical experts.